Welcome to our new monthly feature focussing on the Scottish investment sector, brought to you in partnership with Beauhurst, the platform that shares rich information on UK based high-growth companies.
31% of Scottish investments during March 2017 were in growth-stage companies.
This represents a considerably larger-than-usual share of investments for growth-stage companies as over the last year, only 12% of deals have been into growth-stage companies.
To complete the picture, 38% of investments in this period were into seed-stage companies and 31% into venture-stage companies.
51.3% of investments went into technology and IP-based companies – a significantly higher proportion than the yearly average, which mirrors the rest of the UK and hovers at about 35%.
In February we saw a spike in both deal numbers (20) and the amount invested (£17.7m). Comparatively March’s figures were 13 and £13.7m respectively, however this was still an increase on January’s numbers.
The biggest equity deal of the month was the £3.6m raised by ZoneFox, a developer of technology that monitors and protects business data, providing alerts in cases of policy breaches.
Antimicrobial therapeutics company NovaBiotics and silicon chip and battery management system developer Dukosi raised £3m and £2m respectively.
Other notable deals include MacRebur who raised £1.27m to develop MR6 plastic pellets made from old plastic bottles and Elasmogen’s £1.2m to develop biologic medication.
Scottish Investment Bank was the most notable investor during the month, investing a total of £7.7m in five deals.
Archangels made two deals investing £4.3m.
Other investment players with one deal each in March were CF Woodford Equity Income Fund, Crowdcube, Deepbridge Venture Capital, IP Group, Par Equity, Seedrs and TRI Capital.
TRI Capital invested £3.6m, CF Woodford Equity Income Fund invested £3m, IP Group invested £2m and Par Equity invested £2m.
Beauhurst is a platform where you can access rich information on UK high-growth companies.